Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nkarta, Inc. - Common Stock (NQ:NKTX)

1.895 +0.025 (+1.34%)
Streaming Delayed Price Updated: 11:52 AM EDT, May 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nkarta, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting
From Nkarta, Inc.
Via GlobeNewswire
3 Biotech Stocks to Watch for Potential Breakthroughs
These biotech stocks have significant upside and realistic breakthrough chances in the current and distant future. 
Via InvestorPlace
NVIDIA To Rally Around 19%? Here Are 10 Other Analyst Forecasts For Friday
Wells Fargo raised the price target for Warner Bros. Discovery, Inc. (NASDAQ: WBD) from $13 to $20. Wells Fargo analyst Steven Cahall upgraded the stock from Equal-Weight to Overweight. Warner Bros.... 
Via Benzinga
Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
SVB Leerink Picks This Well-Positioned NK Cell-Focused Stock, Sees 117% Upside
Via Benzinga
Expert Ratings for Nkarta
Analysts have provided the following ratings for Nkarta (NASDAQ:NKTX) within the last quarter: 
Via Benzinga
EXCLUSIVE: Top 10 Searched Tickers On Benzinga Pro In December 2022: Where Do Tesla, Apple, AMC Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2022
Via Benzinga
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds. 
Via TheNewswire.com
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's trading, 138 companies set new 52-week lows. 
Via Benzinga
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
By Ernest Dela Aglanu, Benzinga 
Via News Direct
VF Corp, Verve Therapeutics And Some Other Big Stocks Moving Lower On Monday
U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Why Nkarta Stock (NKTX) Is Volatile During Monday's Session?
Nkarta Inc (NASDAQ: NKTX) shares are trading lower by 5.82% to $8.09, reversing after trading higher during the pre-market session, after the company announced updated data from its Phase 1 dose... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
The biggest pre-market stock movers for Monday include many Chinese shares that traders will want to keep an eye on today! 
Via InvestorPlace
Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting
From Nkarta, Inc.
Via GlobeNewswire
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds. 
Via Benzinga
7 Unknown Biotech Stocks That Could Rocket in 2023
Unknown biotech stocks that are poised for a big rally in 2023. Emerging biotech companies with a promising clinical pipeline. 
Via InvestorPlace
Cowen Slashes Price Target On This Stock By Over 78%; Also Check Out Some Other Big PT Changes
Cowen & Co. cut the price target for The RealReal, Inc. (NASDAQ: REAL) from $14 to $3. RealReal shares fell 0.7% to $3.1388 in pre-market trading. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2022
  
Via Benzinga
Will Another Enlivex Innovation Break The Glass Ceiling For Solid Tumor Treatments?
Cell therapy — the use of stem cells and various engineered immune cells to target difficult-to-treat diseases like cancer and autoimmune conditions — has arguably been one of the big breakthroughs in... 
Via Benzinga
Positive Clinical Results Put Nkarta Stock on the Fast Track
NKTX stock is a fast mover, and a recent share-price bump came in the wake of exciting data from a "killer cell" anti-cancer research program. 
Via InvestorPlace
Executives Buy More Than $32M Of 3 Stocks
Although US stocks closed sharply lower on Friday, there were a few notable insider trades. 
Via Benzinga
How Is The Market Feeling About Nkarta Inc. - Common Stock?
Nkarta Inc. - Common Stock's (NASDAQ:NKTX) short percent of float has risen 8.05% since its last report. The company recently reported that it has 1.84 million shares sold short,... 
Via Benzinga
34 Stocks Moving In Tuesday's Mid-Day Session
Gainers Avadel Pharmaceuticals plc. (NASDAQ: AVDL) shares gained 36.3% to $5.74. Shares closed down 36% on Monday, seemingly on no news. Avadel issued a press release Tuesday... 
Via Benzinga
71 Biggest Movers From Yesterday
Gainers Evoke Pharma, Inc. (NASDAQ: EVOK) shares jumped 118.5% to close at $0.86 on Tuesday. The FDA granted new drug product exclusivity to Evoke Pharma's Gimoti (... 
Via Benzinga
Futures Slide Ahead Of Tech Earnings Deluge
Markets in general are preoccupied by the prospect of tighter monetary policy conditions from global central banks to stem rising prices. 
Via Talk Markets
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.